Merck, Ridgeback Announce New Molnupiravir Data From Late-Stage COVID-19 Study

  • Merck & Co Inc MRK and Ridgeback Biotherapeutics announced that the Annals of Internal Medicine had published additional data from the Phase 3 MOVe-OUT trial of Lagevrio (molnupiravir) in non-hospitalized COVID-19 patients at high risk for progressing to severe disease.
  • A lower proportion of molnupiravir-treated participants in the modified intent-to-treat population had an acute care visit or a COVID-19-related acute care visit versus a placebo.
  • 7.2% of participants who received Lagevrio reported an acute care visit through Day 29, versus 10.6% of placebo participants, with a relative risk reduction of 32.1%.
  • Related: See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization.
  • 6.6% of participants who received Lagevrio reported a COVID-19-related acute care visit, versus 10.0% of placebo participants, with a RRR of 33.8%.
  • Based on a post hoc analysis, fewer Lagevrio-treated participants required respiratory interventions versus placebo-treated participants, with a RRR of 34.3%. 
  • Lagevrio is being evaluated for post-exposure prophylaxis in the MOVe-AHEAD Phase 3 study of Lagevrio in preventing the spread of COVID-19 within households.
  • Price Action: MRK shares are up 0.07% at $89.90 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!